PMID- 24034663
OWN - NLM
STAT- MEDLINE
DCOM- 20140602
LR  - 20211217
IS  - 1751-7176 (Electronic)
IS  - 1524-6175 (Print)
IS  - 1524-6175 (Linking)
VI  - 15
IP  - 9
DP  - 2013 Sep
TI  - Nebivolol monotherapy in younger adults (younger than 55 years) with 
      hypertension: a randomized, placebo-controlled trial.
PG  - 687-93
LID - 10.1111/jch.12169 [doi]
AB  - Nebivolol, a vasodilatory beta1-blocker, may be well suited for the hemodynamics of 
      the younger hypertensive patient. In this 8-week trial, 18- to 54-year-olds with 
      a diastolic blood pressure (DBP) of 95 mm Hg to 109 mm Hg who completed a 4-week 
      placebo-only phase were randomized to receive nebivolol (5 mg/d, titrated to 
      10-20 mg/d based on achievement of blood pressure <140/90 mm Hg [n=427]) or 
      placebo (n=214). Primary and secondary efficacy parameters were changes in trough 
      seated DBP and systolic blood pressure (SBP), respectively. Safety parameters 
      included adverse events (AEs). The baseline mean age was 45.3 years; SBP/DBP, 
      154/100 mm Hg; and heart rate, 78 beats per minute. Completion rates were 91.3% 
      (nebivolol) and 88.3% (placebo). At endpoint, there was a significant effect of 
      nebivolol over placebo for DBP (-11.8 mm Hg vs -5.5 mm Hg, P<.001) and SBP (-13.7 
      mm Hg vs -5.5 mm Hg, P<.001). Total AE rates were 34.7% (nebivolol) and 32.2% 
      (placebo). Nebivolol monotherapy is efficacious and well tolerated in adults 
      younger than 55 years of age with increased DBP.
CI  - (c)2013 Wiley Periodicals, Inc.
FAU - Giles, Thomas D
AU  - Giles TD
AD  - Tulane University, New Orleans, LA.
FAU - Khan, Bobby V
AU  - Khan BV
FAU - Lato, June
AU  - Lato J
FAU - Brener, Lillian
AU  - Brener L
FAU - Ma, Yimin
AU  - Ma Y
FAU - Lukic, Tatjana
AU  - Lukic T
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20130716
PL  - United States
TA  - J Clin Hypertens (Greenwich)
JT  - Journal of clinical hypertension (Greenwich, Conn.)
JID - 100888554
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Benzopyrans)
RN  - 0 (Ethanolamines)
RN  - 030Y90569U (Nebivolol)
SB  - IM
MH  - Adolescent
MH  - Adrenergic beta-Antagonists/pharmacology/*therapeutic use
MH  - Adult
MH  - Age Factors
MH  - Antihypertensive Agents/pharmacology/*therapeutic use
MH  - Benzopyrans/pharmacology/*therapeutic use
MH  - Blood Pressure/drug effects/physiology
MH  - Double-Blind Method
MH  - Ethanolamines/pharmacology/*therapeutic use
MH  - Female
MH  - Heart Rate/physiology
MH  - Humans
MH  - Hypertension/*drug therapy/physiopathology
MH  - Male
MH  - Middle Aged
MH  - Nebivolol
MH  - Prospective Studies
MH  - Severity of Illness Index
MH  - Treatment Outcome
MH  - Young Adult
PMC - PMC8033872
EDAT- 2013/09/17 06:00
MHDA- 2014/06/03 06:00
PMCR- 2013/07/16
CRDT- 2013/09/17 06:00
PHST- 2013/04/19 00:00 [received]
PHST- 2013/06/18 00:00 [revised]
PHST- 2013/06/19 00:00 [accepted]
PHST- 2013/09/17 06:00 [entrez]
PHST- 2013/09/17 06:00 [pubmed]
PHST- 2014/06/03 06:00 [medline]
PHST- 2013/07/16 00:00 [pmc-release]
AID - JCH12169 [pii]
AID - 10.1111/jch.12169 [doi]
PST - ppublish
SO  - J Clin Hypertens (Greenwich). 2013 Sep;15(9):687-93. doi: 10.1111/jch.12169. Epub 
      2013 Jul 16.